Presentations

      Exposure to cigarette smoke constituents in adult Polish smokers of conventional and a prototype cigarette that heats rather than burns tobacco

      Haziza, C.; Jarus-Dziedzic, K.; Lindner, D.; Forte, N.; Birthistle, K.; Magnette, J.

      Conference date
      Sep 6, 2010
      Conference name
      Society for Research on Nicotine and Tobacco (SRNT) Europe 2010
      Link to more information
      Link to more information
      Topic
      Summary

      Objectives: This study was conducted to test the hypothesis that cigarettes that heat rather than burn tobacco reduce exposure to potentially harmful smoke constituents. The levels of biomarkers of exposure (BoExp) to selected potentially harmful cigarette smoke constituents were measured in smokers of conventional lit-end cigarettes (CC), smokers who switched to a prototype test cigarette (TC) that heats rather than burns tobacco, and smokers who stopped smoking (SC) for 5 days. Methods: This was a controlled, randomized, open label, 3 arm parallel group, single centre confinement study conducted in Poland (NCT # 00812279) and performed according to GCP principles. A total of 112 Caucasian smokers of both genders with acceptable health conditions, aged between 23 and 55 years, with a daily consumption of 10 30 cc for at least the last 5 consecutive years, were enrolled. Smokers smoked cc for 2 days (baseline) and were subsequently randomised to one of the study arms: continuing to smoke cc, switching to TC, or switching to smoking cessation (SC) for 5 consecutive days. Except for the SC arm, smoking was allowed ad libitum. The primary objective was to demonstrate a reduction in exposure to carbon monoxide (measured by per cent carboxyhemoglobin [%COHB] in blood), benzene (measured by excretion of s-phenylmercapturic acid [S-PMA] in urine), and NNK (measured by excretion of 4-(methylnitroamino)-1-(3-pyridyl)-1-butanol and glucuronide conjugates [total NNAL] in urine). Additional selected smoke constituents were evaluated. CYP1A2 enzyme activity and safety parameters were also assessed. Results: %COHB, S PMA, and total NNAL were significantly reduced.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.